| Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma (NCT07619937) | The First Affiliated Hospital of Zhengzhou University | 2022-07-22 |
| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) (NCT05461430) | Travera Inc | 2022-07-15 |
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) (NCT05432193) | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | 2022-07-13 |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (NCT05451849) | TCR2 Therapeutics | 2022-06-21 |
| HAIC Combined With Donafenib and Sintilimab for Unresectable ICC (NCT05348811) | Zhongda Hospital | 2022-06-13 |
| Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients (NCT05411133) | Arbele Pty Ltd | 2022-05-30 |
| A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (NCT05346484) | Imugene Limited | 2022-05-17 |
| Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors (NCT05311618) | NGM Biopharmaceuticals, Inc | 2022-05-11 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT05253053) | TransThera Sciences (Nanjing), Inc. | 2022-04-13 |
| Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors (NCT05194735) | Alaunos Therapeutics | 2022-04-04 |
| Safety and Efficacy of EUS-guided Gallbladder Drainage Under Endoscopist-directed Conscious Sedation (NCT07704021) | Azienda Unita Sanitaria Locale di Piacenza | 2022-04-01 |
| Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors (NCT05215574) | NGM Biopharmaceuticals, Inc | 2022-03-31 |
| Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers (NCT04645160) | National Cancer Institute (NCI) | 2022-03-04 |
| 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant (NCT02379377) | M.D. Anderson Cancer Center | 2022-02-15 |
| Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). (NCT04566133) | National Cancer Institute (NCI) | 2022-02-15 |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors (NCT04683939) | BioNTech SE | 2022-01-18 |
| GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma (NCT05215665) | Tianjin Medical University Cancer Institute and Hospital | 2022-01-15 |
| Registry for Advanced Endoscopy (NCT05187312) | Region Stockholm | 2022-01-14 |
| A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors (NCT05194072) | Seagen, a wholly owned subsidiary of Pfizer | 2022-01-12 |
| Association Between Cell-free Nucleic Acid in Blood, Urine and Microbiome in Stool With Pancreatobiliary Cancer (NCT05596370) | Seoul National University Hospital | 2022-01-06 |
| PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma. (NCT05207735) | Henan Cancer Hospital | 2022-01-01 |
| Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma (NCT04919642) | TransThera Sciences (Nanjing), Inc. | 2021-12-07 |
| Milademetan in Advanced/Metastatic Solid Tumors (NCT05012397) | Rain Oncology Inc | 2021-11-01 |
| Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma (NCT04895046) | Walid Shaib, MD | 2021-10-11 |
| A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (NCT04853017) | Elicio Therapeutics | 2021-10-04 |
| HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors (NCT05124743) | Alaunos Therapeutics | 2021-09-24 |
| National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (NCT04145141) | National Cancer Institute (NCI) | 2021-07-28 |
| A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors (NCT04801095) | Wellmarker Bio | 2021-07-14 |
| Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer (NCT04727541) | AIO-Studien-gGmbH | 2021-07-08 |
| Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NCT04913337) | NGM Biopharmaceuticals, Inc | 2021-06-09 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma (NCT04717687) | Poitiers University Hospital | 2021-05-01 |
| A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma (NCT04648319) | American University of Beirut Medical Center | 2021-04-15 |
| Biomarker Discovery in Patients With Advanced Biliary Tract Cancer (NCT04871321) | CHA University | 2021-04-14 |
| Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors (NCT04764084) | Peking University Cancer Hospital & Institute | 2021-04-01 |
| Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT04742959) | TransThera Sciences (Nanjing), Inc. | 2021-03-14 |
| Deep Liver Phenotyping and Immunology Study (NCT04946773) | University of Oxford | 2021-03-12 |
| Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients (NCT04753996) | Mayo Clinic | 2021-03-08 |
| Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy (NCT04676633) | Sirnaomics | 2021-03-01 |
| Neoadjuvant Therapy in Biliary Adenocarcinoma (NCT04480190) | Jordan Kharofa | 2021-02-04 |
| A Study of ICP-192 in Patients With Advanced Solid Tumors (NCT04565275) | Beijing InnoCare Pharma Tech Co., Ltd. | 2021-02-01 |
| Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients (NCT06570174) | Yonsei University | 2021-01-07 |
| ENHANCED RECOVERY AFTER BILIARY TRACT SURGERY (NCT04633382) | Vitebsk State Medical University | 2021-01-01 |
| A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma (NCT04668976) | Benaroya Research Institute | 2020-11-25 |
| A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection (NCT04856761) | Fudan University | 2020-11-01 |
| PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) (NCT04484636) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-10-28 |
| The PLATON Network (NCT05489250) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-10-28 |
| Hepatobiliary Tumors Tissue Samples Acquisition (NCT04445532) | Peking Union Medical College Hospital | 2020-10-11 |
| TCF-001 TRACK (Target Rare Cancer Knowledge) Study (NCT04504604) | TargetCancer Foundation | 2020-10-01 |
| A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors (NCT04866836) | The First Affiliated Hospital with Nanjing Medical University | 2020-10-01 |
| Prospective Evaluation of Biliary Tissue Sampling With ERCP (NCT04572711) | Mayo Clinic | 2020-10-01 |
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations (NCT04521686) | Eli Lilly and Company | 2020-10-01 |
| Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors (NCT04383210) | Elevation Oncology | 2020-09-29 |
| Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer (NCT04304781) | Danielle Kim Turgeon | 2020-09-22 |
| Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers (NCT04430738) | Seagen, a wholly owned subsidiary of Pfizer | 2020-09-15 |
| REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors (NCT04526106) | Elevar Therapeutics | 2020-09-02 |
| Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma (NCT04340986) | Assistance Publique - Hôpitaux de Paris | 2020-09-02 |
| BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours (NCT04421820) | Bold Therapeutics, Inc. | 2020-08-28 |
| Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers (NCT04459273) | Jonsson Comprehensive Cancer Center | 2020-08-27 |
| Liver Cancer Registry Platform (NCT04510740) | iOMEDICO AG | 2020-08-09 |
| A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies (NCT04440943) | Celldex Therapeutics | 2020-08-04 |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S (NCT04430842) | Quadriga Biosciences, Inc. | 2020-07-20 |
| Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer (NCT04561453) | University of Washington | 2020-07-08 |
| the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients (NCT04415190) | Central Hospital, Nancy, France | 2020-06-01 |
| Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer (NCT04308174) | Asan Medical Center | 2020-05-20 |
| Advanced Endoscopy During COVID-19 (NCT04385147) | Al-Azhar University | 2020-05-18 |
| Study of Pembrolizumab and Olaparib in Bile Duct Cancer (NCT04306367) | Georgetown University | 2020-04-01 |
| A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies (NCT04316078) | Sheba Medical Center | 2020-03-15 |
| A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer (NCT04137289) | Boehringer Ingelheim | 2020-03-11 |
| Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement (NCT04256980) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-03-03 |
| Clinical Effect and Safety of PDT and RFA for Unresectable EHCC (NCT04301999) | First People's Hospital of Hangzhou | 2020-03-01 |
| A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion (NCT04238715) | Eisai Co., Ltd. | 2020-01-22 |
| Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations (NCT04233567) | Sameek Roychowdhury | 2020-01-16 |
| RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma (NCT05028439) | First People's Hospital of Hangzhou | 2020-01-01 |
| Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors (NCT03991832) | University Health Network, Toronto | 2019-12-31 |
| Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma (NCT04076761) | Sunnybrook Health Sciences Centre | 2019-12-11 |
| Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors (NCT04157985) | Dan Zandberg | 2019-11-15 |
| Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers (NCT03801915) | National Cancer Institute (NCI) | 2019-11-13 |
| Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC (NCT04066491) | EMD Serono Research & Development Institute, Inc. | 2019-09-20 |
| Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers (NCT04077372) | Stanford University | 2019-09-16 |
| Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study (NCT04243057) | Beijing Tsinghua Chang Gung Hospital | 2019-08-30 |
| Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies (NCT04149691) | Celon Pharma SA | 2019-07-19 |
| Efficacy of Fistulotomy for Biliary Cannulation (NCT04037007) | Coordinación de Investigación en Salud, Mexico | 2019-07-03 |
| Trastuzumab in HER2-positive Biliary Tract Cancer (NCT03613168) | Changhoon Yoo | 2019-06-01 |
| PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer (NCT04099888) | PCI Biotech AS | 2019-05-23 |
| Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study (NCT03951324) | Innovative Digestive Health Education and Research Inc | 2019-05-10 |
| A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (NCT03872947) | Toray Industries, Inc | 2019-04-26 |
| Fluorescence QRH-882260 Peptide Imaging in the Bile Duct (NCT03438435) | D. Kim Turgeon, MD | 2019-04-22 |
| Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors (NCT03895970) | Peking Union Medical College Hospital | 2019-04-20 |
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (NCT03907852) | TCR2 Therapeutics | 2019-04-15 |
| M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) (NCT03833661) | EMD Serono Research & Development Institute, Inc. | 2019-03-26 |
| The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) (NCT03896958) | SpeciCare | 2019-03-21 |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers (NCT03829436) | Tempest Therapeutics | 2019-03-20 |
| Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images (NCT03852836) | IHU Strasbourg | 2019-02-26 |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers (NCT03801083) | Udai Kammula | 2019-02-19 |
| Bilioenteric Anastomosis by Magnetic Compressive Technique (NCT03774589) | First Affiliated Hospital Xi'an Jiaotong University | 2019-02-01 |
| Magnetic Compressive Anastomosis for Biliojejunostomy and Pancreaticojejunostomy During Whipple's Procedure (NCT03792048) | First Affiliated Hospital Xi'an Jiaotong University | 2019-02-01 |
| Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (NCT03339843) | Jules Bordet Institute | 2018-12-19 |
| Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection (NCT03779035) | Tianjin Medical University Cancer Institute and Hospital | 2018-12-15 |
| Trial of IRE in Cholangiocarcinoma (NCT03769753) | Memorial Sloan Kettering Cancer Center | 2018-12-05 |